Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Tyra Biosciences announced a $400 million underwritten offering of common stock and pre-funded warrants. The financing expands the company’s capital base but creates near-term dilution pressure for existing shareholders.
Tyra Biosciences said on Sept. 14 that it priced an underwritten offering combining common stock with pre-funded warrants, with gross proceeds of $400 million before underwriting discounts and offering expenses. The announcement identified the issuer as Tyra Biosciences, a clinical-stage company developing precision medicines focused on FGFR biology.
The transaction is a financing event rather than a clinical or regulatory update. PR Newswire’s announcement excerpt did not disclose the number of common shares or pre-funded warrants issued, the offering price, the expected net proceeds, or the allocation of the funds.
The immediate connection is to TYRA’s capital structure: newly issued common stock increases the share count, while pre-funded warrants can also become common stock subject to their terms. The proceeds give the company additional cash to fund its development programs, but the release excerpt did not specify which trials, research activities, or operating expenses will receive the money.
The size of the financing is clear, but the terms needed to quantify dilution were not included in the available announcement excerpt. The next relevant disclosures are the final offering documents and subsequent securities filings, which should establish the securities issued, pricing, warrant terms, underwriting costs, and the company’s post-transaction share count.
The $400 million financing strengthens TYRA’s runway but puts near-term pressure on existing holders through new equity and warrant issuance.
The financing improves TYRA’s funding capacity for its clinical-stage pipeline, but the equity and pre-funded warrant structure makes dilution the immediate offset; the announcement excerpt does not disclose the securities count or pricing needed to size that effect. The read should remain balanced until the final prospectus and subsequent filing establish the post-offering share count, warrant terms, net proceeds, and updated cash position.
The trade read changes if the final documents show materially favorable pricing, limited incremental share issuance, or a clearly disclosed funding runway that reduces near-term financing risk.
CoverageSource: PR Newswire · Published here MON, SEP 14 · 6:45 AM ET · the only report in this recordHow this is decided →
PR NEWSWIRE / FILEEarlier context and later coverage are dated relative to this report. Automatically linked reports may cover a broader event.
No later reports linked yet.
Follow this story to find new evidence in your Following desk.
TYRA receives $400 million of gross financing to support development of its FGFR-focused precision medicines without relying on an immediately announced debt transaction.
The common-stock and pre-funded-warrant structure increases the potential share count, while the announcement excerpt does not disclose the pricing or number of securities needed to quantify dilution.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →